Acute toxicity and preliminary clinical outcomes of concurrent radiation therapy and weekly docetaxel and daily cisplatin for head and neck cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 11, 2005, Pages 639-644

  Kitamoto, Yoshizumi ^a   Akimoto, Tetsuo ^a   Ishikawa, Hitoshi ^a   Nonaka, Tetsuo ^a   Katoh, Hiroyuki ^a   Nakano, Takashi ^a   Ninomiya, Hiroshi ^a   Chikamatsu, Kazuaki ^a   Furuya, Nobuhiko ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute toxicity; Chemotherapy; Cisplatin; Docetaxel; Radiation therapy

Indexed keywords

CISPLATIN; DOCETAXEL;

ADULT; AGED; ARTICLE; BEAM THERAPY; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CANCER; HUMAN; KIDNEY DYSFUNCTION; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MUCOSAL BLEEDING; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; RADIATION DOSE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUCOSITIS; RADIOTHERAPY, CONFORMAL; TAXOIDS; TREATMENT OUTCOME;

EID: 30444434740     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi175     Document Type: Article

References (32)

1. Cooper JS, Farnan NC, Asbell SO, Rotman M, Marcial V, Fu KK, et al. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 1996;77:1905-11.
2. Hu KS, Harrison LB. Altered fractionation in the treatment of head and neck cancer. Curr Oncol Rep 1999;1:110-23.
3. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
4. Adelstein DJ, Tan EH, Lavertu P. Treatment of head and neck cancer: The role of chemotherapy. Crit Rev Oncol Hematol 1996;24:97-116.
5. Adelstein DJ. Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1999;13:689-98, v-vi.
6. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 1991;67:915-21.
7. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995;6:339-55, 363-8.
8. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992;22:613-7.
9. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995;71:1194-8.
10. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:533-7.
11. Couteau C, Chouaki N, Leyvraz S, Oulid-Aissa D, Lebecq A, Domenge C, et al. A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer 1999;81:457-62.
12. Airoldi M, Cattel L, Cortesina G, Giordano C, Pedani F, Recalenda V, et al. Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: Pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol 2004;27:155-63.
13. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 5th ed. New York Tront: Wiley-Liss 1997.
14. Akimoto T, Mitsuhashi N, Sakurai H, Takahashi T, Yamakawa M, Hayakawa K, et al. The result of radiation therapy for hypopharyngeal carcinoma: impact of accelerated hyperfractionation on prognosis. Jpn J Clin Oncol 1996;26:169-74.
15. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
16. Kaplan EL, Meier PL. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
17. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-8.
18. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
19. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55.
20. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, al Sarraf M, Mowry PA, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 1990;66:1861-8.
21. Adelstein DJ, Kalish LA, Adams GL, Wagner H Jr, Oken MM, Remick SC, et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136-42.
22. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 1994;12: 169-82.
23. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992;30:444-50.
24. Hainsworth JD, Burris HA 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-8.
25. Hainsworth JD, Burris HA 3rd, Greco FA. Weekly administration of docetaxel (Taxotere): Summary of clinical data. Semin Oncol 1999; 26(3 Suppl 10):19-24.
26. Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, et al. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: A dose finding study. Lung Cancer 2003;39:173-7.
27. Nugyen LN, Ang KK. Radiotherapy for cancer of the head and neck: Altered fractionation regimens. Lancet Oncol 2002;3:693-701.
28. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 1998;16:1318-24.
29. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338: 1798-804.
30. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161-71.
31. Kodaira T, Fuwa N, Furutani K, Tachibana H, Yamazaki T. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 2005;35:173-6.
32. Fujii M, Tsukuda M, Satake B, Kubota A, Kida A, Kohno N, et al. Japan Cooperative Head and Neck Oncology Group (JCHNOG). Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol 2004;9:107-12.